SOURCE: Eugene Science, Inc.

May 11, 2006 08:00 ET

Eugene Science Reports Successful Vitafoods International 2006 Exhibition; Strong Interest In Company's Cholesterol Lowering CholZero™ Products

LOS ANGELES, CA -- (MARKET WIRE) -- May 11, 2006 -- Eugene Science, Inc. (OTC BB: EUSI), a developer and marketer of advanced nutraceutical products, today announced it has completed a highly successful exhibition at Vitafoods International 2006.

Held in Geneva, Switzerland from May 9 to 11, Vitafoods International is the largest and most important nutraceutical event in Europe with approximately 5,000 industry visitors including leading distributors, wholesalers, retailers and importers. This represents a 17 percent attendance increase over last year reflecting growing awareness and market demand for nutraceutical products.

The Company also announced that its exhibition at Vitafoods this year is supported by the Korea Trade-Investment Promotion Agency under the Korean Government's Ministry of Commerce, Industry and Energy. Eugene Science's CZ™ and CholZero™ have been designated by the Ministry as one of Korea's Top-tiered Products. Additionally, Eugene Science's Vitafood International 2006 exhibition was partially supported by the Korean Small and Medium Business Administration.

"Functional foods and food ingredients that address health care issues of global importance are always of great interest, with cholesterol and heart disease hot topics this year," said Dr Erika Lee, Vice President-Marketing, Eugene Science. "CholZero™ and CZ™, with its patented water soluble process, generated strong interest since -- unlike the conventional plant sterols in the market -- CholZero™ can be added to an unlimited range of food, beverage and supplement products and offers high efficacy."

"The European consumer market for nutraceuticals is quite sophisticated so CholZero™, as a safe and effective treatment for high cholesterol, was especially well received," Dr. Lee said. "We met with close to 200 prospective European wholesale, retail and distribution customers, many of whom we will be talking to about creating new sales opportunities in the weeks and months ahead."

About Eugene Science

Eugene Science is a global biotechnology company focused on tackling ailments such as heart diseases, obesity and diabetes through technological innovation and product development in the nutraceutical field. As its first commercial heart disease product, Eugene Science has developed a patented, nanoscience-based water soluble product called CZ™, a cholesterol lowering functional food ingredient for health conscious consumers, available in capsule form or as a food or beverage additive. CZ™ contains natural plant sterols that help maintain healthy cholesterol levels in the body by inhibiting cholesterol absorption. These plant sterols have been shown in clinical studies to lower cholesterol and are approved by the United States Food and Drug Administration (FDA) for health claims related to their cholesterol lowering efficacy. Eugene Science intends to license its CZ™ line of products to companies worldwide. Headquartered in Bucheon, Kyunggi-Do, Korea, Eugene Science was founded in 1997. Please visit

This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Eugene Science's management's current expectations and are subject to risks, uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Eugene Science as of the date of the press release, and Eugene Science assumes no obligation to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, and customer, consumer and other intentions, expectations and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Eugene Science's results of operations is detailed in Eugene Science's filings with the United States Securities and Exchange Commission available at

Contact Information

  • Investor Relations Contact:
    Capital Group Communications
    Richard Carpenter or Mark Bernhard
    VP Investor Relations
    email: Email Contact
    (415) 332-7200